Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

2000/10/06 by Simone Silvestri, S. Silvestri, Mary V. Seeman +11 · 311 citations
Medicine · Neuroscience · Psychology · #Antipsychotic #Dopamine #Dopamine receptor #Dopamine receptor D2 #Haloperidol #Internal medicine #Medicine #Neurotransmitter Receptor Influence on Behavior #Olanzapine #Pharmacology #Psychiatry #Psychology #Raclopride #Receptor #Risperidone #Schizophrenia (object-oriented programming) #Schizophrenia research and treatment #Sertindole #Tardive dyskinesia #Tryptophan and brain disorders

paper · doi:10.1007/s002130000532

published in Psychopharmacology 152(2), 174-180 (Springer Science+Business Media)

openalex publication_date 2000/10/06 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/26

Citations

• A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS

Cited by

• Antipsychotic drug action, novel treatment targets, and the failure of current clinical trial designs in evaluating new target molecules
• Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
• Schizophrenia and disordered sensorimotor control: challenges, mechanisms and opportunities
• Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
• Blinded Prospective Evaluation of Computer-Based Mechanistic Schizophrenia Disease Model for Predicting Drug Response
• Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal‐related relapse
• Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice
• Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study
• Behavioral adaptation in C. elegans produced by antipsychotic drugs requires serotonin and is associated with calcium signaling and calcineurin inhibition. [europepmc]
• Frontal feedback-related potentials in nonhuman primates: modulation during learning and under haloperidol. [europepmc]
• D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. [europepmc]
• The nature of dopamine dysfunction in schizophrenia and what this means for treatment. [europepmc]
• Chronic clozapine reduces rat brain arachidonic acid metabolism by reducing plasma arachidonic acid availability. [europepmc]
• Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function. [europepmc]
• Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism. [europepmc]
• Is schizophrenia a dopamine supersensitivity psychotic reaction? [europepmc]
• Glutamate and dopamine in schizophrenia: an update for the 21st century. [europepmc]
• Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia. [europepmc]
• Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status. [europepmc]
• Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review. [europepmc]
• A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia. [europepmc]
• A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. [europepmc]
• State-dependent effects of the D 2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia. [europepmc]
• Biased antagonism of CXCR4 avoids antagonist tolerance. [europepmc]
• The differential actions of clozapine and other antipsychotic drugs on the translocation of dopamine D2 receptors to the cell surface. [europepmc]
• Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia. [europepmc]
• Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia. [europepmc]
• Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. [europepmc]
• The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus. [europepmc]
• Management of Tardive Syndrome: Medications and Surgical Treatments. [europepmc]
• A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse. [europepmc]
• Accumbens D2-MSN hyperactivity drives antipsychotic-induced behavioral supersensitivity. [europepmc]
• Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis. [europepmc]